Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter

NACompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

April 18, 2018

Study Completion Date

April 18, 2018

Conditions
Malignant Pleural Effusion
Interventions
DEVICE

Active Comparator: Approved Uncoated PleurX Indwelling Pleural Catheter

DEVICE

Experimental: Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)

Trial Locations (19)

13210

SUNY Upstate Hospital, Syracuse

21287

Johns Hopkins Hospital, Baltimore

27599

UNC Hospital, Chapel Hill

27710

Duke University, Durham

33612

Moffitt Cancer Center, Tampa

35801

Heart Center Research, Huntsville

37232

Vanderbuilt University, Nashville

46260

St. Vincent Medical Group, Indianapolis

60611

Northwestern Unversity, Chicago

63110

Washington Universtiy School of Medicine, Barnes Jewish Hospital, St Louis

68198

University of Nebraska Medical Center, Omaha

77030

University of Texas, MD Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute, Salt Lake City

94305

Stanford University School of Medicine/ Stanford Cancer Institute, Stanford

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deconess Medical Center West, Boston

Unknown

Southmead Hospital, Bristol

Oxford Center for Respiratory Medicine, Churchill Hospital, Oxford

Great Western Hospital, Swindon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CareFusion

INDUSTRY

NCT02649894 - Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter | Biotech Hunter | Biotech Hunter